Adverse effects cause varenicline discontinuation: A meta-analysis

Current Drug Safety

Volumn 11, Issue 1, 2016, Pages 78-85

  Drovandi, Aaron D ^a   Chen, Carla C ^b   Glass, Beverley D ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Adherence; Adverse effects; Nicotine addiction; Smoking cessation; Varenicline

Indexed keywords

PLACEBO; VARENICLINE; NICOTINIC AGENT;

ADVERSE DRUG REACTION; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; MEDICATION COMPLIANCE; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SMOKING CESSATION; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEDICATION ADHERENCE; NICOTINIC AGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; VARENICLINE;

EID: 84959933861     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886311207040282     Document Type: Article

References (43)

1. th March 2015).
2. Scollo MM, Winstanley MH. Tobacco smoking in Australia: Facts and Issues. 4th Edition. Melbourne, Cancer Council Victoria; 2012. www.tobaccoinaustralia.org.au(last accessed 30th March 2015)
3. World Health Organization. WHO Report on the Global Tobacco Epidemic: Enforcing bans on tobacco advertising, promotion and sponsorship. 2013. www.who.int/tobacco/global_report/2013/en/(last accessed 30th March 2015)
4. Australian Government. National Tobacco Strategy 2012-2018. 2012. www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Content/national_ts_2012_2018_html (last accessed 30th March 2015)
5. Wakefield MA, Durkin S, Spittal M et al. Impact of tobacco control policies and mass media campaigns on monthly adult smoking prevalence. Am J Public Health 2008; 98(8): 1443-50
6. Wakefield M, Loken B, Hornik R. Use of mass media campaigns to change health behaviour. Lancet 2010; 376: 1261-71
7. American Cancer Society. Guide to Quitting Smoking. 2013. www.cancer.org/acs/groups/cid/documents/webcontent/002971-pdf.pdf (last accessed 30th March 2015)
8. Huang Y, Li W, Yang L, Jiang Y, Wu Y. Long-term efficacy and safety of Varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials. Am J Public Health 2012; 20: 355-65
9. Gonzales D, Rennard SI, Nides M et al. Varenicline, an α4β2 Nicotinic Acetylcholine receptor partial agonist, vs sustainedrelease bupropion and placebo for smoking cessation: A randomized controlled trial. J Am Med Assoc 2006; 296(1): 47-55
10. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation (Review). Cochr Database Sys Rev 2012; 11: CD000146
11. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochr Database Sys Rev 2014; 1: CD000031
12. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review). Cochr Database Sys Rev 2013; 5: CD009329
13. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179(2): 135-44
14. Tashkin DP, Rennard S, Hays T, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 2011; 139(3): 591-9
15. Rennard S, Hughes J, Cinciripini PM et al. A randomized placebocontrolled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012; 14(3): 343-50
16. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6: 300
17. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation (Review). Cochr Database Sys Rev 2012; 1: CD006103
18. Australian Medicines Handbook Pty Ltd. Chapter 18: Psychotropic Drugs. Australian Medicines Handbook 2014. Adelaide, Australia. Australian Medicines Handbook; 2014: 806-811. (Last accessed 30th March, 2015).
19. Catz SL, Jack LM, McClure JB et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res 2011; 13(5): 361-8
20. Vrijens B, De Geest S, Hughes DA et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73(5): 691-705
21. Liberman JN, Lichtenfeld MJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a communitybased patient setting. J Manag Care Pharm 2013; 19(2): 125-31
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097
23. Bolliger C, Issa J, Posadas-Valay R. et al. Effects of varenicline in adult smokers: A multinational, 24-week, randomized, doubleblind, placebo-controlled study. Clin Ther 2011; 33(4): 465-77
24. Fagerström K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ 2010; 341: c6549
25. Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008; 24(7): 1931-41
26. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Arch Intern Med 2006; 166: 1561-8
27. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571-7
28. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010; 121: 221-9
29. Tsai S, Cho H, Cheng H, et al. A randomized, placebo-controlled trial of varenicline, a selective α2β4 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Therap 2007; 29(6): 1027-39
30. Wang C, Xiao D, Chan KPW, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: A placebo-controlled, randomized study. Respirology 2009; 14: 384-92
31. Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007; 23(4): 793-801
32. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs pacebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006; 296(1): 56-63
33. Halperin AC, McAfee TA, Jack LM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat 2009; 36: 428-34
34. Boudrez H, Gratziou C, Messig M, Metcalfe M. Effectiveness of varenicline as an aid to smoking cessation: results of an inter- European observational study. Curr Med Res Opin 2011; 27(4): 769-75
35. Bobak A. Varenicline: implications for the field. J Smok Cessat 2007; 2(1): 8-11
36. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibasi T, Reeves KR. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29(6): 1040-56
37. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 2013; 170:1460-67
38. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji A. Use of varenicline for 4 weeks before quitting smoking: decrease in ad ;lib smoking and increase in smoking cessation rates. Arch Intern Med 2011; 171(8): 770-7
39. Hawk LW, Ashare RL, Lohnes SF, et al. The effects of extended pre-quit varenicline treatment on smoking behaviour and shortterm abstinence: A randomized clinical trial. Clin Pharmacol Ther 2012; 91(2): 172-80
40. Tonstad S, Tønnesen P, Hajek P, Williame KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 2006; 296(1): 64-71
41. Von WM, Raymond V, Paradis PE. The long term costeffectiveness of varenicline (12-week standard course + 12-week extended course) vs other smoking cessation strategies in Canada. Int J Clin Pract 2014; 68(5): 639-46
42. Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherence. Nicotine Tob Res 2010; 12(6): 574-81
43. Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Pre Adher 2010; 4: 355-62.